Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 January 2024 | Story Leonie Bolleurs | Photo Sonia Small
Prof Corinna Walsh
Prof Corinna Walsh says the PEA POD Infant Body Composition System works by directly measuring an infant’s body weight and volume, and then uses these measurements to calculate the body fat percentage, fat mass, and fat-free mass.

Nutritional and growth patterns during early life have been associated with health, development, and well-being throughout the life cycle. It is also associated with risks for developing obesity and non-communicable diseases, such as cardiometabolic diseases, later in life. These are the findings of Prof Corinna Walsh, Professor in the Department of Nutrition and Dietetics.

Maternal and child health

”In line with national priorities, a strong research focus area of the Faculty of Health Sciences and the School of Health and Rehabilitation Sciences is maternal and child health,” she says. She goes on to mention that the Department of Nutrition and Dietetics has established a reputable research programme. This programme focuses primarily on the nutritional status of pregnant women and how the early environment to which they are exposed during and after pregnancy affects short- and long-term health outcomes of the offspring.

“In our previous work, the assessment of birth outcomes of infants was, however, limited by the lack of equipment to analyse body composition. The research that we can conduct with the PEA POD® provides us with immense additional potential,” remarks Prof Walsh.

She explains, “The PEA POD Infant Body Composition System is an infant-sized air displacement plethysmography system. It works by directly measuring an infant’s body weight and volume, and then uses these measurements to calculate the body fat percentage, fat mass, and fat-free mass.

According to her, the assessment of body volume takes two minutes. “The PEA POD technique also does not require collection of any fluids and does not expose the infant to radiation. It can be performed as often as required without any risks and be used up to a maximum of 8-10 kg body weight, from birth to about eight months,” she says.

Advanced technology

In the context of research on infant body weight and composition, there is a need for accurate measurement techniques that can differentiate between fat mass and fat-free mass. Prof Walsh is of the opinion that traditional measures such as body mass index (BMI) and weight for length have limitations in this regard, as they do not provide a clear distinction between these components. Furthermore, BMI may not be reliable for assessing adiposity or obesity in paediatric populations, and it can vary significantly with age and gender.

Addressing these challenges, the PEA POD equipment offers advanced technology that allows for highly accurate quantification of infant body composition. This technological capability opens up opportunities to study the effects of early-life nutrition on growth and the developmental mechanisms that may lead to later comorbidities. So, when it comes to researching infant body weight and composition, the PEA POD equipment plays a crucial role in providing precise data and insights.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept